Dr. Reddy’s is eligible for first to market, 180 days of generic drug exclusivity for lenalidomide capsules in 2.5-mg and 20-mg strengths.

Dr. Reddy’s Laboratories SA, Switzerland completed its acquisition of Haleon’s global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy category outside of the United ...

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has received an ‘IND AA+/Stable’ rating from India Ratings & Research for its bank facilities, reflecting a ...

Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it ...

A high-level overview of Dr. Reddy's Laboratories Limited (RDY) stock. View (RDY) real-time stock price, chart, news, analysis, analyst reviews and more.

Dr. Reddy's Laboratories, operating in the Pharmaceuticals sector and classified as a Largecap on the BSE, currently has its share price at ₹1303. The stock has experienced fluctuations today ...

Dr. Reddy’s remains focused on building a global pipeline of valued products, including several generic injectables and biosimilars. Year to date, shares of Dr. Reddy’s have gained 1.6% ...

In recent trading, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) have crossed above the average analyst 12-month target price of $15.40, changing hands for $15.53/share. When a stock ...

Dr. Reddy's Laboratories Ltd. 500124 shares shed 1.08% to 1,346.75 Indian rupees Monday, on what proved to be an all-around favorable trading session for the stock market, with the BSE SENSEX ...

Dr. Reddy’s Laboratories has initiated a voluntary recall of Levetiracetam in 0.75% Sodium Chloride Injection (1,000 mg/100 mL), identified as Lot Number A ...

Shares of Dr. Reddy's Laboratories Ltd. 500124 inched down 0.17% to 1,222.65 Indian rupees Thursday, on what proved to be an all-around dismal trading session for the stock market, with the BSE ...